Clinical Trial Update: A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC [Phase 2]

View source ↗

Summary

A Phase II, single-arm study evaluating tislelizumab in combination with anlotinib and platinum-based chemotherapy as perioperative therapy for resectable stage…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Platinum-based doublet chemotherapy
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING